We found that RAI2 could decrease the proliferation and invasion in GC cells through reducing PD-L1 expression and related to tumor-infiltrating lymphocytes (TILs), suggesting that it may be an innovative treatment option for GC patients. This evidence concerns the gene CD274 and neoplasm.